



MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

January 24th, 2026

To,

National Stock Exchange of India Limited
Listing & Compliance Department
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai - 400051, India

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Subject: Outcome of Board Meeting pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we are pleased to inform you Board of Directors of Medicamen Organics Limited at their meeting held on Saturday, January 24th, 2026 at the Registered office of the Company situated at -10, Community Centre No.2, Ashok Vihar Phase-II, Delhi -110052 India inter-alia, considered the following matters:-

1. The Board has accorded the consent for the change in variation in the objects of the issue as stated in the prospectus dated June 26, 2024 for the Initial Public Offering (IPO) of the Company form Funding of expenses proposed to be incurred towards Product registration in the international markets to meet Working Capital requirement, subject to the approval of shareholders in the ensuring the Extra Ordinary General Meeting by way of Postal ballot notice for alteration in the objects of the initial public offer (IPO) for which amount was raised and extension of timeline, which will be sent to the shareholders of the Company and the stock exchange(s) in due course.

2. The Board has approved the provisions of Section 197 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V to the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and other applicable provisions of law, if any, the consent and approval of the members of the Company be and is hereby accorded for the payment of remuneration to the Directors of the Company, including managing director(s), whole-time director(s) and manager, exceeding 11% of Net Profit of the Company calculated as per the provision of Section 198 of the Companies Act, 2013.

The consent and approval of the members of the Company be and is hereby accorded for the remuneration payable to any one managing director or whole-time director or manager for exceeding 5% of the net profits of the Company and, where there is more than one such director, the total remuneration payable to all such directors and the manager taken together for exceeding 10% of the net profits of the Company calculated as per the provision of Section 198 of the Companies Act, 2013.

3. Re-appointment of Mr. Ashutosh Gupta (Din: 00039995) as a Whole Time Director, to hold office for a period of 5 (Five) years i.e., commencing from April 30, 2026 to April 29, 2031 (both days inclusive)

The Board of Directors at its meeting held today i.e., January 24, 2026, discussed and approved the proposal of the Nomination and Remuneration Committee ('NRC') of the Board of Directors of the Company for the re-appointment of Mr. Ashutosh Gupta. His re-appointment is subject to approval by the Members of the Company.

Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH



MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

The details as required under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is given in the **Annexure-A**.

4. Please refer to our communication dated 13th March, 2025 w.r.t. to allotment of 4,65,910 Fully Convertible Warrants at Issue Price of Rs.64.39/- on preferential basis, in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in their meeting held today i.e. January 24, 2026 inter-alia, considered and approved the allotment of 4,65,910 equity shares having face value of Rs. 10/- each at an issue price of Rs. 64.39/- each (including a premium of Rs. 54.39/- each), consequent upon the conversion of 4,65,910 Warrants issued at an Issue Price of Rs. 64.39/-each, to the following persons belonging to the “Promoter/Promoter Group”, on preferential basis, upon receipt of balance amount aggregating to Rs. 2,24,99,959/- (Rupees Two Crore Twenty-Four Lakh Ninety-Nine Thousand Nine Hundred Fifty-Nine Only) at the rate of Rs. 48.29/- (Rupees Sixty-Four and Thirty-Nine Paise Only) per warrant (being 75% of the issue price per warrant) from the allottees pursuant to the exercise of their rights of conversion into equity shares in accordance with the provisions of SEBI (ICDR) Regulations, 2018:

Name of Allottee	No. of warrants held allotted	No. of warrants applied for conversion	No of equity shares allotted	Amount received being 75% of the issue price per warrant	No. of warrants pending for conversion
Bal Kishan Gupta	4,65,910	4,65,910	4,65,910	2,24,99,959	0
Total	4,65,910	4,65,910	4,65,910	2,24,99,959	0

Pursuant to members approval, these warrants were allotted, in terms of SEBI (ICDR) Regulations, 2018 to “Promoter/Promoter Group” on preferential basis, at an Issue Price of Rs. 64.39/- per warrant on payment of Rs. 10.00/- per warrant, being 25% of the Issue Price, entitling the warrants holders to get their warrants converted into equal number of Equity Shares of the Company by paying remaining 75% i.e., Rs. 48.29/- within 18 months from the date of warrant allotment.

Consequent to today's conversation of warrants/allotment of Equity Shares, the issued and paid-up capital of the Company stands increased to Rs 1,21,65,9,100/-consisting of 1,21,65,910 equity shares of Rs. 10/- each.

The new equity shares so allotted, shall rank pari-passu with the existing equity shares of the Company.

Please note that there are no outstanding warrants pending for conversion, as the entire allotment of warrants has been duly and fully converted into equity shares.

We reiterate that the entire amount received from the conversion will be infused into Medicamen's growth strategy—an approach that is both ambitious and disciplined, aimed at balancing rapid expansion with long-term sustainability.

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as **Annexure B** to this letter.

Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH



MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | **GSTIN:** 07AABCM4302P1ZF

5. To seek members' approval through the process of postal ballot for the above-said today's board decision and approved the draft notice of Postal Ballot and authorized Director/ KMP to issue the same to the concerned, appointment of M/s. Anu Malhotra & Associates as Scrutinizer for postal ballot and matters related thereto.

The notice of the postal ballot will be sent separately to the Stock Exchange and to the Members of the Company and will also be available on the Company's website at www.medicamenorganics.com and on the website of the stock exchange i.e. National Stock Exchange of India Limited at www.nseindia.com, in due course.

The Board meeting commenced at 03:00 PM and concluded at 07:02 PM

This is for your information and records.

Thanking You,

For Medicamen Organics Limited

Bal Kishan Gupta
Managing Director
DIN: 00032772

Place: New Delhi

Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN:** 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN:** 05AABCM4302P3ZH



MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Annexure -A

Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended), read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S.no.	Particulars	Mr. Ashutosh Gupta
1.	Reason for change viz.appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment
2.	Date of appointment/ re - appointment/ cessation (as applicable) & term of appointment/reappointment	Term of reappointment: The existing term of Mr. Ashutosh Gupta as the Whole Time Director of the Company will end on April 30,2026 In view of the above, the Board of Directors recommended the reappointment of Mr. Ashutosh Gupta as the Whole Time Director of the Company for the term of 5 (Five) consecutive years Effective from April 30, 2026, to April 29, 2031 subject to the approval by the Members.
3.	Brief Profile (in case of appointment)	Mr. Ashutosh Gupta is a Whole-time Director of our Company. He holds the degree of Bachelor of Business Administration from Guru Jambheshwar University, Hissar. He has experience in this field of 18 years he earlier worked with listed Company names Medicamen Biotech Limited and later joined Medicamen Organics Limited. He has been awarded with the degree of Honorary Doctorate in contribution in Export of Pharma Industry in the year 2021. He has been Chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India) from 2014-2016, a Government of India Council, specifically created for promotion of pharmaceutical exports from India
4.	Disclosure of relationships between directors (in case of appointment of a director)	Son of Bal Kishan Gupta, our Managing Director and Chairman
5.	Information pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 ('Circulars')	Mr. Ashutosh Gupta is not debarred from holding the office of a director by virtue of any SEBI order or any other such authority as required under the circulars.
6.	Other listed companies where the Director is associated	NA

Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH



MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Annexure-B

The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are as under:

S.no.	Particulars	Disclosures																				
1.	Type of securities proposed to be Issued	Equity Shares pursuant to conversion of warrants																				
2.	Type of issuance	Preferential Allotment																				
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Allotment of 4,65,910 equity shares having face value of Rs. 10/- each at an issue price of Rs. 64.39/- each (including a premium of Rs. 54.39/- each), consequent upon the conversion of 4,65,910 Warrants issued at an Issue Price of Rs. 64.39/-each, upon receipt of balance amount aggregating to Rs. 2,24,99,959/-																				
Additional information in case of preferential issue:																						
4.	Name and number of the Investor(s)	Mr. Bal Kishan Gupta																				
5.	Post allotment of securities – outcome of the subscription, issue price / allotted price (in case of convertibles),	<table border="1"> <thead> <tr> <th>Name of the Allottee(s)</th> <th>Pre Issue Equity Holding before allotment</th> <th>No. of Shares allotted upon conversion of warrant</th> <th>Post issue Equity Holding after exercise of Warrants</th> </tr> </thead> <tbody> <tr> <td></td> <td>No. of shares</td> <td>%</td> <td></td> <td>No. of shares</td> <td>%</td> </tr> <tr> <td>Bal Kishan Gupta</td> <td>61,02,650</td> <td>52.16</td> <td>4,65,910</td> <td>65,68,560</td> <td>53.99</td> </tr> </tbody> </table>					Name of the Allottee(s)	Pre Issue Equity Holding before allotment	No. of Shares allotted upon conversion of warrant	Post issue Equity Holding after exercise of Warrants		No. of shares	%		No. of shares	%	Bal Kishan Gupta	61,02,650	52.16	4,65,910	65,68,560	53.99
Name of the Allottee(s)	Pre Issue Equity Holding before allotment	No. of Shares allotted upon conversion of warrant	Post issue Equity Holding after exercise of Warrants																			
	No. of shares	%		No. of shares	%																	
Bal Kishan Gupta	61,02,650	52.16	4,65,910	65,68,560	53.99																	
		<p>Warrants had been allotted on 13th March, 2025 carrying a right to subscribe to 1 Equity Share per warrant on receipt of amount at the rate of Rs. 10.00/- per warrant (being 25% of the issue price per warrant).</p> <p>Hence, 4,65,910 Equity Shares have been allotted on receipt of balance amount at the rate of Rs. 48.29 per warrant (being 75% of the issue price per warrant)</p>																				
6.	In case of - intimation on conversion of securities or on lapse of the tenure of the instrument	Exercise of 4,65,910 warrants into 4,65,910 fully paid-up Equity Shares of Rs.10/- each at an issue price of Rs. 64.39/- each.																				

Works:

Unit-1 : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

Unit-2 : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH